{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:14:38Z","timestamp":1790673278067,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud University Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10067-018-4171-6","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T18:29:00Z","timestamp":1531160940000},"page":"2715-2722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-7348","authenticated-orcid":false,"given":"W. M. T.","family":"van den Hombergh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. O.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Teesselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. K. A.","family":"Knaapen-Hans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. H. J.","family":"van den Hoogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"4171_CR1","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Muller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kumanovics G, Coleiro B, Feierl E, Szucs G, von Muhlen CA, Riccieri V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho PC, Kotter I, Simsek I, de la Pena Lefebvre PG, Hachulla E, Seibold JR, Rednic S, Stork J, Morovic-Vergles J, Walker UA (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809\u20131815","journal-title":"Ann Rheum Dis"},{"key":"4171_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0889-857X(03)00025-5","volume":"29","author":"B White","year":"2003","unstructured":"White B (2003) Interstitial lung disease in scleroderma. Rheum Dis Clin N Am 29:371\u2013390","journal-title":"Rheum Dis Clin N Am"},{"key":"4171_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1164\/ajrccm.149.6.8004317","volume":"149","author":"AU Wells","year":"1994","unstructured":"Wells AU, Cullinan P, Hansell DM, Rubens MB, Black CM, Newman-Taylor AJ, Du Bois RM (1994) Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 149:1583\u20131590","journal-title":"Am J Respir Crit Care Med"},{"key":"4171_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1164\/ajrccm.154.2.8756813","volume":"154","author":"J Behr","year":"1996","unstructured":"Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, Konig G, Fruhmann G (1996) Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 154:400\u2013406","journal-title":"Am J Respir Crit Care Med"},{"key":"4171_CR5","doi-asserted-by":"publisher","first-page":"L1202","DOI":"10.1152\/ajplung.00351.2003","volume":"286","author":"RF Hamilton Jr","year":"2004","unstructured":"Hamilton RF Jr, Parsley E, Holian A (2004) Alveolar macrophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changes. Am J Physiol Lung Cell Mol Physiol 286:L1202\u2013L1209","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"4171_CR6","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1164\/ajrccm.151.5.7735620","volume":"151","author":"AM Southcott","year":"1995","unstructured":"Southcott AM, Jones KP, Li D, Majumdar S, Cambrey AD, Pantelidis P, Black CM, Laurent GJ, Davies BH, Jeffery PK (1995) Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med 151:1604\u20131612","journal-title":"Am J Respir Crit Care Med"},{"key":"4171_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1183\/09031936.95.08020266","volume":"8","author":"AU Wells","year":"1995","unstructured":"Wells AU, Lorimer S, Majumdar S, Harrison NK, Corrin B, Black CM, Jeffery PK, Bois RMD (1995) Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. Eur Respir J 8:266\u2013271","journal-title":"Eur Respir J"},{"key":"4171_CR8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/pgmj.2006.046417","volume":"82","author":"SJ Bourke","year":"2006","unstructured":"Bourke SJ (2006) Interstitial lung disease: progress and problems. Postgrad Med J 82:494\u2013499","journal-title":"Postgrad Med J"},{"key":"4171_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foldvari I, Furst DE, Muller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M, and the EUSTAR co-authors (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68:620\u2013628","journal-title":"Ann Rheum Dis"},{"key":"4171_CR10","first-page":"S818","volume":"58","author":"C Nannini","year":"2008","unstructured":"Nannini C, West CP, Erwin PJ, Matteson EL (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and a meta-analysis of randomized controlled trials and observational prospective cohort studies8. Arthritis Rheum 58:S818\u2013S818","journal-title":"Arthritis Rheum"},{"key":"4171_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1164\/rccm.200705-655OC","volume":"177","author":"C Strange","year":"2008","unstructured":"Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP, the Scleroderma Lung Study Research Group* (2008) Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 177:91\u201398","journal-title":"Am J Respir Crit Care Med"},{"key":"4171_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s100670050138","volume":"18","author":"EM Davas","year":"1999","unstructured":"Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:455\u2013461","journal-title":"Clin Rheumatol"},{"key":"4171_CR13","first-page":"731","volume":"29","author":"R Giacomelli","year":"2002","unstructured":"Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, Fulminis A, de Luca A, Farina G, Candela M, Generini S, de Francisci A, Tirri E, Proietti M, Bombardieri S, Gabrielli A, Tonietti G, Cerinic MM (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29:731\u2013736","journal-title":"J Rheumatol"},{"key":"4171_CR14","first-page":"2371","volume":"29","author":"B Griffiths","year":"2002","unstructured":"Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P (2002) Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29:2371\u20132378","journal-title":"J Rheumatol"},{"key":"4171_CR15","first-page":"1121","volume":"30","author":"G Mittal","year":"2003","unstructured":"Mittal G, Udwadia Z, Joshi VR (2003) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 30:1121\u20131122 author reply 1122","journal-title":"J Rheumatol"},{"key":"4171_CR16","first-page":"298","volume":"29","author":"I Pakas","year":"2002","unstructured":"Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29:298\u2013304","journal-title":"J Rheumatol"},{"key":"4171_CR17","first-page":"838","volume":"20","author":"RM Silver","year":"1993","unstructured":"Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838\u2013844","journal-title":"J Rheumatol"},{"key":"4171_CR18","first-page":"1325","volume":"25","author":"G Varai","year":"1998","unstructured":"Varai G, Earle L, Jimenez SA, Steiner RM, Varga J (1998) A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 25:1325\u20131329","journal-title":"J Rheumatol"},{"key":"4171_CR19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.7326\/0003-4819-132-12-200006200-00004","volume":"132","author":"B White","year":"2000","unstructured":"White B, Moore WC, Wigley FM, Xiao HQ, Wise RA (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947\u2013954","journal-title":"Ann Intern Med"},{"key":"4171_CR20","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962\u20133970","journal-title":"Arthritis Rheum"},{"key":"4171_CR21","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666","journal-title":"N Engl J Med"},{"key":"4171_CR22","doi-asserted-by":"publisher","first-page":"R124","DOI":"10.1186\/ar2534","volume":"10","author":"C Nannini","year":"2008","unstructured":"Nannini C, West CP, Erwin PJ, Matteson EL (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 10:R124","journal-title":"Arthritis Res Ther"},{"key":"4171_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1183\/09031936.05.00034905","volume":"26","author":"N Macintyre","year":"2005","unstructured":"Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26:720\u2013735","journal-title":"Eur Respir J"},{"issue":"Suppl","key":"4171_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1183\/09041950.005s1693","volume":"16","author":"PH Quanjer","year":"1993","unstructured":"Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC (1993) Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal Official Statement of the European Respiratory Society. Eur Respir J 16(Suppl):5\u201340","journal-title":"Eur Respir J"},{"key":"4171_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NS Goh","year":"2008","unstructured":"Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ et al (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177:1248\u20131254","journal-title":"Am J Respir Crit Care Med"},{"key":"4171_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","volume":"161","author":"American Thoracic Society","year":"2000","unstructured":"American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161:646\u2013664","journal-title":"Am J Respir Crit Care Med"},{"key":"4171_CR27","unstructured":"Interstitial Lung Disease. [cited; Available from: \n                    http:\/\/www.thoracic.org\/statements\/insterstitial-lung-disease.php"},{"key":"4171_CR28","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5301\/jsrd.5000205","volume":"1","author":"D Launay","year":"2016","unstructured":"Launay D (2016) Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease. J Scleroderma Relat Disord 1:234\u2013240","journal-title":"J Scleroderma Relat Disord"},{"key":"4171_CR29","first-page":"1339","volume":"165","author":"VM Montori","year":"2001","unstructured":"Montori VM, Guyatt GH (2001) Intention-to-treat principle. CMAJ 165:1339\u20131341","journal-title":"CMAJ"},{"key":"4171_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","volume":"319","author":"S Hollis","year":"1999","unstructured":"Hollis S, Campbell F (1999) What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319:670\u2013674","journal-title":"BMJ"},{"key":"4171_CR31","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study II Investigators (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719","journal-title":"Lancet Respir Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4171-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T19:50:36Z","timestamp":1562701836000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4171-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["4171"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4171-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"6 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}